BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biopharmaceutical company, today announced six abstracts presenting data at the American Thoracic Society (ATS) medical conference in San Diego, California May 15 – 20, 2009. Under a worldwide collaboration, Dynavax and its pharmaceutical partner AstraZeneca are discovering and developing novel therapies which represent a new strategy for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
